Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Research Determines Why Different Cancers Display Similar Profiles

By LabMedica International staff writers
Posted on 17 Oct 2018
A team of cancer researchers has identified a molecular mechanism that may explain why gene expression profiles are similar in late stage cancers from different organs.

The use of modern chemotherapeutic techniques to treat epithelial cancers leads to the development of multiple resistance mechanisms, including the generation of highly aggressive, small cell neuroendocrine carcinoma (SCNC). More...
SCNC patients have a poor prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. In particular, whether distinct cancer types accomplish this “reprogramming” through the same mechanism has been unclear.

Investigators at the University of California, Los Angeles (USA) reported in the October 5, 2018, issue of the journal Science that while healthy prostate and lung cells have very different patterns of gene expression, they display almost identical patterns when they transform into small cell cancers.

The investigators found that a common set of defined oncogenic drivers reproducibly reprogrammed normal human prostate and lung epithelial cells and transformed them into small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. They identified shared active transcription factor binding regions in the reprogrammed prostate and lung SCNCs by integrative analyses of epigenetic and transcriptional landscapes.

"Small cell cancers of the lung, prostate, bladder, and other tissues were long thought to be similar in name alone - and they were treated by oncologists as different entities," said senior author Dr. Owen Witte, professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles. "Over the past few years, though, researchers have increasingly begun to realize that there are similarities in the cancers, and that's what our work confirms. Our study revealed shared "master gene regulators" - the key proteins that control expression of multiple genes in small cell cancer cells. Studying the network of the master gene regulators could lead to a new way of combating deadly cancers."

Overall, the results presented in this study suggest that neuroendocrine cancers arising from distinct epithelial tissues may share common vulnerabilities that could be exploited for the development of new drugs to treat SCNCs.

Related Links:
University of California, Los Angeles


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.